Profile data is unavailable for this security.
About the company
Turnstone Biologics Corp. is a clinical-stage biotechnology company. The Company is focused on developing new medicines to treat and cure patients with solid tumors. It is developing tumor infiltrating lymphocytes (TIL) therapies for the potential treatment of multiple solid tumors. It is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program. It is advancing TIDAL-01, its lead Selected TIL product candidate, for the treatment of multiple solid tumor indications. TIDAL-01 utilizes an unbiased identification and functional screening process to isolate and selectively expand the greatest breadth of tumor-reactive TILs from the patient’s tumor. Its next Selected TIL program, TIDAL-02, is being designed to encompass a next generation streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.
- Revenue in USD (TTM)19.31m
- Net income in USD-55.24m
- Incorporated2014
- Employees80.00
- LocationTurnstone Biologics Corp9310 Athena Circle, Suite 300LA JOLLA 92037United StatesUSA
- Phone+1 (347) 897-5988
- Fax+1 (302) 655-5049
- Websitehttps://www.turnstonebio.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anebulo Pharmaceuticals Inc | 0.00 | -10.49m | 61.20m | 2.00 | -- | 9.43 | -- | -- | -0.4087 | -0.4087 | 0.00 | 0.2502 | 0.00 | -- | -- | 0.00 | -86.04 | -- | -95.37 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -36.63m | 61.28m | 10.00 | -- | -- | -- | -- | -0.9859 | -0.9859 | 0.00 | -4.12 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.0045 | -- | -- | -- | -- | 30.30 | -- | -- | -- |
| Avrobio Inc | 0.00 | 30.31m | 61.50m | 13.00 | 1.98 | 0.6921 | 2.01 | -- | 0.6903 | 0.6903 | 0.00 | 1.98 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| Immix Biopharma Inc | 0.00 | -18.21m | 62.05m | 14.00 | -- | 2.22 | -- | -- | -0.9263 | -0.9263 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -77.50 | -- | -90.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| RetinalGenix Technologies Inc | 0.00 | -2.09m | 62.25m | 0.00 | -- | -- | -- | -- | -0.1205 | -0.1205 | 0.00 | -0.0797 | 0.00 | -- | -- | -- | -929,284.40 | -9,163.75 | -- | -- | -- | -- | -- | -- | -- | -543.50 | -- | -- | -- | -- | 46.58 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -23.72m | 62.67m | 13.00 | -- | -- | -- | -- | -1.57 | -1.57 | 0.00 | -0.2801 | 0.00 | -- | -- | 0.00 | -266.70 | -- | -520.49 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -21.91 | -- | -- | -- |
| Turnstone Biologics Corp | 19.31m | -55.24m | 63.83m | 80.00 | -- | 4.14 | -- | 3.31 | -2.68 | -2.68 | 0.9103 | 0.6672 | -- | -- | -- | 241,325.00 | -- | -- | -- | -- | -- | -- | -285.92 | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| Ikena Oncology Inc | 3.85m | -70.09m | 64.42m | 34.00 | -- | 0.4147 | -- | 16.74 | -1.58 | -1.58 | 0.0861 | 3.22 | 0.0237 | -- | -- | 89,488.38 | -43.11 | -29.72 | -46.56 | -34.62 | -- | -- | -1,821.54 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| Bioqual Inc | 62.86m | 957.02k | 64.85m | 108.00 | 67.76 | 1.67 | 18.49 | 1.03 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 64.94m | 9.00 | -- | 3.32 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
| Mural Oncology PLC | 0.00 | -207.45m | 65.15m | 117.00 | -- | 0.2436 | -- | -- | -12.43 | -12.43 | 0.00 | 15.81 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.29 | -- | -- | -- |
| VolitionRX Ltd | 797.03k | -34.91m | 65.17m | 110.00 | -- | -- | -- | 81.77 | -0.4603 | -0.4603 | 0.0104 | -0.1901 | 0.0425 | -- | 6.32 | 7,245.73 | -188.25 | -111.92 | -- | -196.20 | -- | -- | -4,425.95 | -10,793.31 | -- | -173.85 | -- | -- | 153.04 | -- | -16.68 | -- | 29.13 | -- |
| Champions Oncology Inc | 49.22m | -9.73m | 65.43m | 230.00 | -- | -- | -- | 1.33 | -0.7183 | -0.7183 | 3.64 | -0.1514 | 1.56 | -- | 6.17 | 214,017.40 | -30.91 | -5.40 | -96.45 | -11.88 | 40.09 | 47.96 | -19.76 | -3.09 | -- | -- | -- | -- | 9.69 | 21.63 | -1,073.54 | -- | 18.50 | -- |
| Intensity Therapeutics Inc | 0.00 | -15.13m | 66.22m | 5.00 | -- | 6.81 | -- | -- | -1.10 | -1.10 | 0.00 | 0.709 | 0.00 | -- | -- | 0.00 | -206.66 | -- | -696.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -22.12m | 66.65m | 31.00 | -- | 1.57 | -- | -- | -1.70 | -1.70 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -54.31 | -58.43 | -56.14 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
Data as of May 16 2024. Currency figures normalised to Turnstone Biologics Corp's reporting currency: US Dollar USD
32.37%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 1.41m | 6.12% |
| Point72 Asset Management LPas of 31 Dec 2023 | 1.38m | 5.99% |
| BofA Securities, Inc.as of 31 Dec 2023 | 892.55k | 3.86% |
| Eventide Asset Management LLCas of 31 Dec 2023 | 708.32k | 3.07% |
| Citadel Advisors LLCas of 31 Dec 2023 | 684.63k | 2.96% |
| PFM Health Sciences LPas of 31 Dec 2023 | 633.31k | 2.74% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 623.90k | 2.70% |
| Sectoral Asset Management, Inc.as of 31 Dec 2023 | 517.65k | 2.24% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 354.21k | 1.53% |
| ExodusPoint Capital Management LPas of 31 Dec 2023 | 266.85k | 1.16% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
